發(fā)布時間：2018-06-01 02:23

  本文選題：腫瘤標志物 + 聯(lián)合檢測�。� 參考：《中國現(xiàn)代醫(yī)學雜志》2017年15期

【摘要】：目的研究常用腫瘤標志物糖鏈抗原(CA125和CA199)、人附睪蛋白4(HE4)、乳酸脫氫酶(LDH)單項及聯(lián)合檢測在上皮性卵巢癌診斷中的臨床價值。方法用化學發(fā)光微粒子免疫檢測法和酶速率法檢測220例上皮性卵巢癌患者、78例卵巢上皮性交界性腫瘤患者、120例卵巢成熟性畸胎瘤患者及162例卵巢子宮內(nèi)膜異位癥患者血清中腫瘤標志物濃度。結(jié)果 (1)上皮性卵巢癌組的CA125、CA199、HE4及LDH高于其他3組(P0.008);(2)4種腫瘤標志物中HE4診斷上皮性卵巢癌的敏感性為73.18%,特異性為98.89%,約登指數(shù)(Youden index)為72.07%,受試者工作特征曲線(ROC曲線)下面積為0.952,綜合其他評價指標,可得出HE4的診斷能力最好;(3)聯(lián)合檢測組中CA125、CA199、HE4及LDH四項聯(lián)合檢測診斷上皮性卵巢癌的敏感性為97.73%,特異性為25.00%,ROC曲線下面積為0.973,其診斷價值最高。結(jié)論 CA125、CA199、HE4及LDH 4項聯(lián)合檢測是診斷上皮性卵巢癌比較理想的腫瘤標志物組合,對卵巢良惡性腫瘤的鑒別診斷具有重要臨床價值。
[Abstract]:Objective to study the clinical value of single and combined detection of carbohydrate chain antigen CA125 and CA199, human epididymal protein 4H4, lactate dehydrogenase (LDH) in the diagnosis of epithelial ovarian cancer. Methods the chemiluminescence microparticle immunoassay and enzyme rate assay were used to detect 220 cases of epithelial ovarian cancer and 78 cases of ovarian epithelial sexual intercourse borderline tumor. 120 cases of ovarian mature teratoma and 162 cases of ovarian endometriosis were detected. Serum tumor markers in patients. Results (1) the sensitivity of HE4 in diagnosis of epithelial ovarian cancer was 73.18, the specificity was 98.89 and the Jordan index (Youden index) was 72.07. The sensitivity of HE4 in diagnosing epithelial ovarian cancer was 73.18, the Youden index was 72.07, and the operating characteristic curve (ROC) was higher than that in the other three groups (P 0.008). The area under it is 0.952. It can be concluded that the diagnostic ability of HE4 is the best. In the combined detection group, the sensitivity of CA125, CA199HE4 and LDH in the diagnosis of epithelial ovarian cancer is 97.73 and the specificity is 25.00. The area under the ROC curve is 0.973.The diagnostic value is the highest. Conclusion the combined detection of CA125, CA199HE4 and LDH is an ideal combination of tumor markers for the diagnosis of epithelial ovarian cancer, and has important clinical value in the differential diagnosis of benign and malignant ovarian tumors.
【作者單位】： 新疆醫(yī)科大學附屬腫瘤醫(yī)院;
【分類號】：R737.31

【參考文獻】

相關(guān)期刊論文 前10條

1 岳娟;劉菲;李艷紅;;卵巢癌早期診斷的血清腫瘤標記物研究進展[J];國際婦產(chǎn)科學雜志;2015年05期

2 侯娟娟;虎淑妍;劉婷婷;張玲;席維岳;鄭紅軍;潘云燕;;血清腫瘤標志物在卵巢癌早期診斷中的臨床價值[J];中國免疫學雜志;2014年08期

3 武春梅;李霞蓮;李玲;尹莉莉;李倩;;聯(lián)合檢測腫瘤標志物在卵巢腫瘤診斷中的應(yīng)用[J];國際檢驗醫(yī)學雜志;2014年06期

4 李洪英;王蘭;;子宮內(nèi)膜異位癥不孕患者血清CA125水平與術(shù)后妊娠結(jié)局的關(guān)系[J];河北醫(yī)學;2014年02期

5 張月萍;;人附睪蛋白4診斷卵巢癌的臨床應(yīng)用[J];中國實驗診斷學;2013年01期

6 沈立松;周韻斕;尚紅;潘柏申;;腫瘤標志物的臨床應(yīng)用建議[J];中華檢驗醫(yī)學雜志;2012年02期

7 辛亞蘭;王卡娜;何榮霞;;血清腫瘤標志物在上皮性卵巢癌早期診斷中研究進展[J];中國婦幼保健;2011年10期

8 范文勇;;血漿CA125在不同婦科疾病中的表達水平及其對療效的評估價值[J];中國當代醫(yī)藥;2011年03期

9 朱亞林;霍穎;徐永居;;血清AFP、CEA、CA19-9、CA125、TSGF聯(lián)檢對卵巢癌的診斷價值[J];放射免疫學雜志;2009年04期

10 秦萬平;林R，

本文編號：1962495